



MEDICHEM IN A FLASH

- Medichem S.A. is a privately owned company, based in Barcelona and founded in 1972
- Our activities: -
- · Active Pharmaceutical Ingredients
- · Chlorhexidine, world leaders
- · Contract Manufacturing
- Process development and manufacture of non-infringing, cGMP Active Pharmaceutical Ingredients (APIs) including Highly Potent APIs
- Team of over 250 highly professional, committed and devoted people
- ISO 9001 & ISO 14001 certified
- Manufacturing sites: Girona (25,000 m²) and Malta (8,800 m²)
- Medichem Manufacturing (Malta) Ltd. founded in 2005
- Nanjing Medichem Biopharmaceutical Development Co. Ltd. (NRC) founded in 2012
- Full respect for the environment at all our sites
- FDA inspected since 1985 Both Celrà and Malta plants have no "Form 483" records



MEDICHEM IN A FLASH

- >55 products in regular production
- >15 products under development
- 40 opportunities for PIV challenge
- 15 opportunities for early launch
- Strong IP team
- 25% people devoted to R&D
- 200 DMFs
- 12 Certificates of Suitability
- Recent Highlights:

- · Opening of a HPAPI modular facillity in Malta
- · Installation of continuous flow reactor at industrial scale in Spain

HISTORY


- · Foundation of the company
 - · Building of the production plant in Santa María de Montcada
- · Relocation of manufacturing facilities to the current production plant in Celrà (Spain)
- 1985 · Celrà plant inspected by the FDA for the first time
- 1986 · Launch of the first product for the US market
- 2004 · Start of plant construction in Malta
- 2007 · Malta plant inspected by the FDA for the first time
 - · Start up of a Biazzi® hydrogenation unit in Celrà
- 2012 · 5th consecutive FDA inspection with no "Form 483" in Celrà
 - · Opening of new R+D center in Nanjing (China)
- Start operations of the new Highly Potent API plant in Malta
 Installation of Continuous Flow Reactor at industrial scale in Spain
- 2015 · 2nd consecutive FDA inspection with no "Form 483" in Malta



LOCATIONS Celrà (Girona) • Barcelona Sant Joan Despí Hal Far (MALTA)







ACTIVE PHARMACEUTICAL INGREDIENTS (API) / HPAPI


- Early API development, offering non-infringing processes. This allows our clients the earliest possible market entry
- Careful selection of projects targeting high value and high growth areas
- Over 45 US DMFs, over 141 DMFs in Europe and 12 Certificates of Suitability
- R&D focused approach with over 75 products in pipeline/porfolio
- Unparalleled US FDA inspection history: no "Form 483" since 1999*
- All relevant ISO and environmental certifications
- Proactive and aggressive approach to carve out our own IP space, currently >25 patent families "in the works"
- Cooperation with the United States and European Pharmacopoeias

*Celrà plant. Total 13 inspections since 1985




PORTFOLIO

- Portfolio: more than 55 products in regular production over 15 therapeutic areas
- Our key therapeutic areas are:



PIPELINE

- Our pipeline is composed of >15 products in various phases of development
- >25 patent families which amount to a total of >80 patents/patent applications
- Investment in R&D around 10% of our turnover
- Among our pipeline, we can find products from key therapeutic areas:





CHLORHEXIDINE

- Regular production since 1985
- Manufacturing 4
 Chlorhexidine compounds:

- · Chlorhexidine Base
- · Chlorhexidine Digluconate 20% solution
- · Chlorhexidine Diacetate
- · Chlorhexidine Dihydrochloride
- Leading Chlorhexidine manufacturer
- Our large volumes enable us to rely on very significant economies of scale in our production
- FDA inspections of our Celrà Plant covered Chlorhexidine
- Chlorhexidine Digluconate registered under REACH (registration no. 01-2119946568-22-0001)
- Chlorhexidine Digluconate notified under the Biocides Product Directive (BPD) - Europe
- Medichem has also pre-registered Chlorhexidine Diacetate and Chlorhexidine Dihydrochloride under REACH

CONTRACT MANUFACTURING

We provide the following CMO/CRO services:

SPAIN -



FLOW CHEMISTRY: Continuous flow reactor at industrial scale in Celrà (Spain). Medichem can provide scale up services from R&D to industrial scale

MALTA —

ADVANTAGEOUS IP SITUATION: Malta gives us a unique advantage concerning IP framework, allowing Medichem to develop and produce APIs in advance of patent expiry and offering first-to-market opportunities to its customers worldwide

HPAPI: We can produce Class 4 HPAPIs with OEL down to 40 ng/m³ within cGMP and FDA inspected environments

CHINA —

CRO SERVICES: in our R&D center in Nanjing (China)

Thanks to our experience, we can provide integrated services to help our clients to reduce time and costs



REGULATORY SUMMARY

- Drug Master Files (DMFs) submitted to the main Health Authorities worldwide (>45 countries)
- 12 Certificates of Suitability / 2 DMFs submitted to EMA (European Medicines Agency)







Fructuós Gelabert, 6-8 08970 Sant Joan Despí (Barcelona) SPAIN Medichem Manufacturing (Malta) Ltd.

HF 61, Hal-Far Industrial Estate BBG 3000 Hal Far MALTA Plant in Spain :: Medichem S.A.

Polígono Industrial de Celrà 17460 Celrà (Girona) SPAIN